{
    "paper_id": "e1a1c64711b3be526f7662305d0c0e3d0aa1f7f8",
    "metadata": {
        "title": "Journal Pre-proof Repositionnement de la chlorpromazine dans le traitement du COVID-19: etude reCoVery Repositionnement de la chlorpromazine dans le traitement du COVID-19 : \u00e9tude reCoVery Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study",
        "authors": [
            {
                "first": "Mario",
                "middle": [],
                "last": "Plaze",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "P\u00f4le Hospitalo-Universitaire",
                    "location": {
                        "addrLine": "Paris 15",
                        "settlement": "Paris",
                        "country": "France"
                    }
                },
                "email": ":m.plaze@ghu-paris.fr"
            },
            {
                "first": "David",
                "middle": [],
                "last": "Attali",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "P\u00f4le Hospitalo-Universitaire",
                    "location": {
                        "addrLine": "Paris 15",
                        "settlement": "Paris",
                        "country": "France"
                    }
                },
                "email": ""
            },
            {
                "first": "Anne-C\u00e9cile",
                "middle": [],
                "last": "Petit",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "P\u00f4le Hospitalo-Universitaire",
                    "location": {
                        "addrLine": "Paris 15",
                        "settlement": "Paris",
                        "country": "France"
                    }
                },
                "email": ""
            },
            {
                "first": "Michael",
                "middle": [],
                "last": "Blatzer",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Institut Pasteur",
                    "location": {
                        "settlement": "Paris",
                        "country": "France"
                    }
                },
                "email": ""
            },
            {
                "first": "Etienne",
                "middle": [],
                "last": "Simon-Loriere",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "G5 Evolutionary Genomics of RNA Viruses",
                    "location": {
                        "settlement": "Paris",
                        "country": "France"
                    }
                },
                "email": ""
            },
            {
                "first": "Fabien",
                "middle": [],
                "last": "Vinckier",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "P\u00f4le Hospitalo-Universitaire",
                    "location": {
                        "addrLine": "Paris 15",
                        "settlement": "Paris",
                        "country": "France"
                    }
                },
                "email": ""
            },
            {
                "first": "Arnaud",
                "middle": [],
                "last": "Cachia",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "INSERM",
                    "location": {
                        "settlement": "Paris",
                        "country": "France"
                    }
                },
                "email": ""
            },
            {
                "first": "Fabrice",
                "middle": [],
                "last": "Chr\u00e9tien",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Institut Pasteur",
                    "location": {
                        "settlement": "Paris",
                        "country": "France"
                    }
                },
                "email": ""
            },
            {
                "first": "Rapha\u00ebl",
                "middle": [],
                "last": "Gaillard",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "P\u00f4le Hospitalo-Universitaire",
                    "location": {
                        "addrLine": "Paris 15",
                        "settlement": "Paris",
                        "country": "France"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "OBJECTIFS : La pand\u00e9mie mondiale actuelle de COVID-19 a touch\u00e9 environ 2 350 000 personnes et fait plus de 160 000 morts. Nous avons observ\u00e9 dans le GHU PARIS Psychiatrie & Neurosciences (site Sainte-Anne, Paris, France) une incidence moins importante de formes symptomatiques de COVID-19 chez les patients (environ 4 %) que dans notre personnel soignant (environ 14 % des infirmiers et m\u00e9decins). Des retours similaires nous sont donn\u00e9s par les unit\u00e9s psyCOVID en France et \u00e0 l'\u00e9tranger. Ces observations nous ont amen\u00e9s \u00e0 formuler l'hypoth\u00e8se que la chlorpromazine (CPZ) pourrait avoir une action prophylactique sur le SARS-CoV-2 et prot\u00e9geraient les patients des formes symptomatiques et virulentes de cette infection. Cette hypoth\u00e8se est coh\u00e9rente avec les propri\u00e9t\u00e9s antivirales connues de la CPZ. En plus de ses effets antipsychotiques classiques, plusieurs \u00e9tudes in vitro ont \u00e9galement d\u00e9montr\u00e9 une activit\u00e9 antivirale de cette ph\u00e9nothiazine via l'inhibition de l'endocytose d\u00e9pendante des clathrines. R\u00e9cemment, des \u00e9tudes ont r\u00e9v\u00e9l\u00e9 un effet anti-MERS-CoV et anti-SARS-CoV-1 de la CPZ. M\u00c9THODES : Dans ce contexte, l'\u00e9tude ReCoVery, bas\u00e9e sur le repositionnement de la CPZmol\u00e9cule avec un excellent profil de tol\u00e9rance et une biodistribution tr\u00e8s \u00e9lev\u00e9e dans la salive, les poumons et le cerveau -vise \u00e0 tester l'hypoth\u00e8se que la CPZ pourrait diminuer l'\u00e9volution d\u00e9favorable de l'infection COVID-19 chez des patients oxyg\u00e9norequ\u00e9rants sans n\u00e9cessit\u00e9 de soins en r\u00e9animation mais aussi r\u00e9duire la contagiosit\u00e9 du SARS-CoV-2. Nous allons r\u00e9aliser pour cela un essai th\u00e9rapeutique pilote de phase III multicentrique, randomis\u00e9, contr\u00f4l\u00e9 (traitement standard vs. CPZ + traitement standard) et en simple insu.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "OBJECTIVES: The ongoing COVID-19 pandemic comprises a total of more than 2 350 000 cases and 160 000 deaths. The interest in anti-coronavirus drug development has been limited so far and effective methods to prevent or treat coronavirus infections in humans are still lacking. Urgent action is needed to fight this fatal coronavirus infection by reducing the number of infected people along with the infection contagiousness and severity. Since the beginning of the COVID-19 outbreak several weeks ago, we observe in GHU PARIS Psychiatrie & Neurosciences (Sainte-Anne hospital, Paris, France) a lower prevalence of symptomatic and severe forms of COVID-19 infections in psychiatric patients (~4 %) compared to health care professionals (~14 %). Similar observations have been noted in other psychiatric units in France and abroad. Our hypothesis is that psychiatric patients could be protected from the severe form of COVID-19 by their psychotropic treatments. Chlorpromazine (CPZ) is a phenothiazine derivative widely used in clinical routine in the treatment of acute and chronic psychoses. This first antipsychotic medication has been discovered in 1952 by Jean Delay and Pierre Deniker at Sainte-Anne hospital. In addition to its antipsychotic effects, several in vitro studies have also demonstrated a CPZ antiviral activity via the inhibition of clathrin-mediated endocytosis. Recently, independent studies revealed that CPZ is an anti-MERS-CoV and an anti-SARS-CoV-1 drug. In comparison to other antiviral drugs, the main advantages of CPZ lie in its biodistribution: (i) preclinical and clinical studies have reported a high CPZ concentration in the lungs (20--200 times higher than in plasma), which is critical because of the respiratory tropism of SARS-CoV-2; (ii) CPZ is highly concentrated in saliva (20-60 times higher than in plasma) and could therefore reduce the contagiousness of COVID-19; (iii) CPZ can cross the blood-brain barrier and could therefore prevent the neurological forms of COVID-19. METHODS: In this context, we will test the hypothesis that CPZ could decrease the unfavorable evolution of COVID-19 infection in oxygen-requiring patients without the need for intensive care, but also reduce the contagiousness of SARS-CoV-2. At this end, we designed a pilot, phase III, multicenter, single blind, randomized controlled therapeutic trial. Efficacy of CPZ will be assessed according to clinical, biological and radiological criteria. The main objective is to demonstrate a shorter Time To Response (TTR) to treatment in the CPZ + standard-of-care (CPZ + SOC) group, compared to the SOC group. Response to treatment is defined by a reduction of at least one level of severity on the WHO-Ordinal Scale for Clinical Improvement (WHO-OSCI). The secondary objectives are to demonstrate in the CPZ + SOC group, compared to the SOC group: A) superior clinical improvement; B) a greater decrease in the biological markers of viral attack by SARS-CoV-2 (PCR, viral load); C) a greater decrease in inflammatory markers (e.g. CRP and lymphopenia); D) a greater decrease in parenchymal involvement (chest CT) on the seventh day post-randomization; E) to define the optimal dosage of CPZ and its tolerance; F) to evaluate the biological parameters of response to treatment, in particular the involvement of inflammatory cytokines. Patient recruitment along with the main and secondary objectives are in line with WHO 2020 COVID-19 guidelines. CONCLUSION: This repositioning of CPZ as anti-SARS-CoV-2 activity offers an alternative and rapid strategy to alleviate the virus propagation and the infection severity and lethality. This CPZ repositioning strategy also avoids numerous developmental and experimental steps, can save precious time to rapidly establish an anti-COVID-19 therapy with well-known, limited and easy to manage side effects. Indeed, CPZ is an FDAapproved drug with an excellent tolerance profile, prescribed for around 70 years, in psychiatry but also in clinical routine in nausea and vomiting of pregnancy, in advanced cancer and also to treat headaches in various neurological conditions. The broad spectrum of CPZ treatment -including antipsychotic, anxiolytic, antiemetic, antiviral, immunomodulatory effects along with inhibition of clathrin-mediated endocytosis and modulation of blood-brain barrier -is in line with the historical French commercial name for CPZ, i.e. LARGACTIL, chosen as a reference to its 'LARGe ACTion' Page 3 of 10 J o u r n a l P r e -p r o o f properties. The discovery of those CPZ properties, as for many other molecules in psychiatry, is both the result of serendipity and careful clinical observations. Using this approach, the field of mental illness could provide innovative therapeutic approaches to fight SARS-CoV-2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "La pand\u00e9mie mondiale en cours de COVID-19 a touch\u00e9 environ 2 350 000 personnes et fait plus de 160 000 morts [1] . C'est la troisi\u00e8me et la plus grave Cette hypoth\u00e8se est coh\u00e9rente avec les propri\u00e9t\u00e9s antivirales connues de plusieurs m\u00e9dicaments psychotropes utilis\u00e9s couramment en psychiatrie, au premier rang desquels la chlorpromazine. Cette ph\u00e9nothiazine, synth\u00e9tis\u00e9e en 1951 par Rh\u00f4ne Poulenc, est utilis\u00e9e depuis 1952 en psychiatrie depuis que Jean Delay et Pierre Deniker, \u00e0 l'h\u00f4pital Sainte-Anne, ont d\u00e9couvert ses propri\u00e9t\u00e9s antipsychotiques [2] . \u00c0 partir des ann\u00e9es 80 ont aussi \u00e9t\u00e9 d\u00e9couvertes les propri\u00e9t\u00e9s antivirales in vitro de cette mol\u00e9cule : contre le virus de la grippe [3] , le VIH [4] , le JC virus [5] , l'enc\u00e9phalite japonaise [6] , le VHC [7] et les alphavirus (Chikungunya, Semliki Forest Virus [8] ).",
            "cite_spans": [
                {
                    "start": 109,
                    "end": 112,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 551,
                    "end": 554,
                    "text": "[2]",
                    "ref_id": null
                },
                {
                    "start": 691,
                    "end": 694,
                    "text": "[3]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 704,
                    "end": 707,
                    "text": "[4]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 722,
                    "end": 725,
                    "text": "[5]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 752,
                    "end": 755,
                    "text": "[6]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 765,
                    "end": 768,
                    "text": "[7]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 822,
                    "end": 825,
                    "text": "[8]",
                    "ref_id": "BIBREF8"
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "Action anti-coronavirus de la chlorpromazine En 2014, deux \u00e9tudes ont mis en \u00e9vidence l'int\u00e9r\u00eat de la chlorpromazine dans l'inhibition in vitro de la r\u00e9plication virale de coronavirus [9, 10] . Dans la premi\u00e8re \u00e9tude, de Wilde et al. ont montr\u00e9 l'efficacit\u00e9 anti-MERS-CoV, anti-SARS-CoV-1 et anti-coronavirus-229E de 4 mol\u00e9cules, dont la chlorpromazine, parmi les 348 mol\u00e9cules test\u00e9es in vitro dans cette \u00e9tude [9] . Les auteurs concluent que la chlorpromazine est l'une des mol\u00e9cules les plus prometteuses pour inhiber les coronavirus chez l'homme. La seconde \u00e9tude met en \u00e9vidence l'efficacit\u00e9 de 27 mol\u00e9cules, dont la chlorpromazine, pour inhiber la r\u00e9plication virale de MERS-CoV et SARS-CoV-1 parmi 290 mol\u00e9cules test\u00e9es [10] . Plus r\u00e9cemment, Cong et al. confirment l'efficacit\u00e9 de la chlorpromazine pour inhiber la r\u00e9plication virale du SARS-CoV-1 et du MERS-CoV sur des lign\u00e9es cellulaires de monocytes d\u00e9riv\u00e9s de macrophages humains [11] . L'efficacit\u00e9 de la chlorpromazine s'av\u00e8re m\u00eame sup\u00e9rieure \u00e0 celle du tor\u00e9mif\u00e8ne et de la chloroquine, deux autres mol\u00e9cules test\u00e9es dans cette \u00e9tude.",
            "cite_spans": [
                {
                    "start": 184,
                    "end": 187,
                    "text": "[9,",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 188,
                    "end": 191,
                    "text": "10]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 412,
                    "end": 415,
                    "text": "[9]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 727,
                    "end": 731,
                    "text": "[10]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 943,
                    "end": 947,
                    "text": "[11]",
                    "ref_id": "BIBREF11"
                }
            ],
            "ref_spans": [],
            "section": "Int\u00e9r\u00eat potentiel de la chlorpromazine dans le traitement du COVID-19"
        },
        {
            "text": "Au niveau des m\u00e9canismes cellulaires, la chlorpromazine affecte l'endocytose d\u00e9pendante des clathrines gr\u00e2ce \u00e0 une interaction avec la dynamine, ce qui emp\u00eache l'entr\u00e9e et l'excr\u00e9tion des virus par les cellules [12, 13] . Ces m\u00e9canismes d'endocytose d\u00e9pendante des clathrines sont indispensables aux coronavirus pour p\u00e9n\u00e9trer dans la cellule [14] . Tr\u00e8s r\u00e9cemment, un article de revue souligne l'int\u00e9r\u00eat d'une strat\u00e9gie th\u00e9rapeutique ciblant la voie de l'endocytose d\u00e9pendante des clathrines pour inhiber la r\u00e9plication virale du SARS-CoV-2 [15] . D'autres m\u00e9canismes d'action de la chlorpromazine pourraient \u00eatre impliqu\u00e9s car elle a montr\u00e9 une inhibition de la r\u00e9plication du MERS-CoV \u00e0 la fois \u00e0 des stades pr\u00e9coces et tardifs d'entr\u00e9e dans la cellule [9] . Au total, la chlorpromazine semble avoir un potentiel d'inhibition large-spectre des coronavirus [9, 10] .",
            "cite_spans": [
                {
                    "start": 211,
                    "end": 215,
                    "text": "[12,",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 216,
                    "end": 219,
                    "text": "13]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 342,
                    "end": 346,
                    "text": "[14]",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 541,
                    "end": 545,
                    "text": "[15]",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 755,
                    "end": 758,
                    "text": "[9]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 858,
                    "end": 861,
                    "text": "[9,",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 862,
                    "end": 865,
                    "text": "10]",
                    "ref_id": "BIBREF10"
                }
            ],
            "ref_spans": [],
            "section": "Int\u00e9r\u00eat potentiel de la chlorpromazine dans le traitement du COVID-19"
        },
        {
            "text": "Le coronavirus SARS-CoV-2 impliqu\u00e9 dans l'\u00e9pid\u00e9mie actuelle de COVID-19 a de nombreuses caract\u00e9ristiques communes avec la famille des coronavirus [16] et a des similarit\u00e9s phylog\u00e9n\u00e9tiques avec le SARS-CoV-1 [17] . Il est donc tr\u00e8s probable qu'une mol\u00e9cule ayant montr\u00e9 une efficacit\u00e9 contre les MERS-CoV et SARS-CoV-1 puisse \u00e9galement avoir une activit\u00e9 anti-SARS-CoV-2. Afin de confirmer l'hypoth\u00e8se de l'action antivirale de la chlorpromazine sur le SARS-CoV-2, une exp\u00e9rimentation pr\u00e9clinique in vitro a d\u00e9but\u00e9 en avril 2020 au laboratoire de haute s\u00e9curit\u00e9 biologique niveau III de l'Institut Pasteur en collaboration avec le GHU PARIS Psychiatrie & Neurosciences.",
            "cite_spans": [
                {
                    "start": 146,
                    "end": 150,
                    "text": "[16]",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 207,
                    "end": 211,
                    "text": "[17]",
                    "ref_id": "BIBREF17"
                }
            ],
            "ref_spans": [],
            "section": "Int\u00e9r\u00eat potentiel de la chlorpromazine dans le traitement du COVID-19"
        },
        {
            "text": "Int\u00e9r\u00eat de la chlorpromazine dans la dysr\u00e9gulation immunitaire du COVID-19 ?",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Int\u00e9r\u00eat potentiel de la chlorpromazine dans le traitement du COVID-19"
        },
        {
            "text": "Dans les cas s\u00e9v\u00e8res de COVID-19, plusieurs \u00e9l\u00e9ments sugg\u00e8rent l'implication d'une dysr\u00e9gulation du syst\u00e8me immunitaire dont les m\u00e9canismes ne sont pas \u00e9lucid\u00e9s \u00e0 l'heure actuelle [18] . La recherche de traitements immunomodulateurs, agissant par diff\u00e9rents m\u00e9canismes et sur diff\u00e9rents types cellulaires, est donc d'un int\u00e9r\u00eat majeur \u00e0 l'heure actuelle. D\u00e8s les ann\u00e9es 1990, plusieurs publications ont soulign\u00e9 les effets immunomodulateurs de la chlorpromazine [19] , notamment par augmentation du taux sanguin d'IgM [20] . Chez la souris, il a \u00e9t\u00e9 montr\u00e9 que la chlorpromazine a un effet protecteur contre le choc septique induit par l'injection d'endotoxines et engendre une baisse conjointe d'IL-2, IL-4, IFN alpha, TNF et GM-CSF, des cytokines pro-inflammatoires, ainsi qu'une augmentation de l'IL-10, une cytokine anti-inflammatoire [21] [22] [23] [24] .",
            "cite_spans": [
                {
                    "start": 180,
                    "end": 184,
                    "text": "[18]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 462,
                    "end": 466,
                    "text": "[19]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 518,
                    "end": 522,
                    "text": "[20]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 839,
                    "end": 843,
                    "text": "[21]",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 844,
                    "end": 848,
                    "text": "[22]",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 849,
                    "end": 853,
                    "text": "[23]",
                    "ref_id": "BIBREF23"
                },
                {
                    "start": 854,
                    "end": 858,
                    "text": "[24]",
                    "ref_id": "BIBREF24"
                }
            ],
            "ref_spans": [],
            "section": "Int\u00e9r\u00eat potentiel de la chlorpromazine dans le traitement du COVID-19"
        },
        {
            "text": "En comparaison \u00e0 d'autres antiviraux, un des avantages de la chlorpromazine r\u00e9side dans sa biodistribution. D'une part, il a \u00e9t\u00e9 d\u00e9montr\u00e9 chez l'animal qu'apr\u00e8s une injection unique de chlorpromazine, les plus hautes concentrations de cette mol\u00e9cule (et de ses m\u00e9tabolites) se situent dans les poumons avec des taux de chlorpromazine 20 \u00e0 200 fois plus \u00e9lev\u00e9s dans les poumons que dans le sang [25, 26] . Cette donn\u00e9e a \u00e9t\u00e9 confirm\u00e9e chez l'humain au cours d'une \u00e9tude post-mortem chez des patients souffrant de schizophr\u00e9nie et trait\u00e9s par chlorpromazine jusqu'\u00e0 leur d\u00e9c\u00e8s [27] . Au vu du tropisme respiratoire du SARS-CoV-2 [28] , la forte distribution pulmonaire de la chlorpromazine pourrait ainsi \u00eatre un atout de cette mol\u00e9cule aux propri\u00e9t\u00e9s antivirales. D'autre part, la chlorpromazine est \u00e9galement fortement concentr\u00e9e dans la salive avec, chez l'humain, des concentrations salivaires 20 \u00e0 60 fois plus \u00e9lev\u00e9es que dans le plasma [29] . Ces fortes concentrations de chlorpromazine dans les glandes salivaires pourraient diminuer la charge virale salivaire et donc r\u00e9duire la contagiosit\u00e9 du SARS-CoV-2.",
            "cite_spans": [
                {
                    "start": 394,
                    "end": 398,
                    "text": "[25,",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 399,
                    "end": 402,
                    "text": "26]",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 575,
                    "end": 579,
                    "text": "[27]",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 627,
                    "end": 631,
                    "text": "[28]",
                    "ref_id": "BIBREF28"
                },
                {
                    "start": 941,
                    "end": 945,
                    "text": "[29]",
                    "ref_id": "BIBREF29"
                }
            ],
            "ref_spans": [],
            "section": "La biodistribution de la chlorpromazine, un avantage dans le traitement du COVID-19"
        },
        {
            "text": "Enfin, la chlorpromazine, de par sa nature lipophile, peut traverser la barri\u00e8re h\u00e9mato-enc\u00e9phalique [30] et pourrait donc avoir un effet th\u00e9rapeutique sur les formes neurologiques d\u00e9crites du COVID-19 [31] . Cette distribution c\u00e9r\u00e9brale, connue de longue date et expliquant son action antipsychotique et ses effets secondaires, a \u00e9t\u00e9 document\u00e9e d\u00e8s les ann\u00e9es 60 \u00e0 l'aide de marquage isotopique chez l'animal puis chez l'humain [32, 33] : la chlorpromazine est d\u00e9tect\u00e9e au sein du tissu c\u00e9r\u00e9bral 15 minutes apr\u00e8s une injection intraveineuse unique, dans diff\u00e9rentes zones telles que le cortex, le noyau caud\u00e9, le putamen et le thalamus. Lors d'une administration chronique chez le rat, les concentrations c\u00e9r\u00e9brales de chlorpromazine sont jusqu'\u00e0 25 fois plus \u00e9lev\u00e9es que les concentrations plasmatiques [34, 35] .",
            "cite_spans": [
                {
                    "start": 101,
                    "end": 105,
                    "text": "[30]",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 202,
                    "end": 206,
                    "text": "[31]",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 429,
                    "end": 433,
                    "text": "[32,",
                    "ref_id": "BIBREF32"
                },
                {
                    "start": 434,
                    "end": 437,
                    "text": "33]",
                    "ref_id": "BIBREF33"
                },
                {
                    "start": 805,
                    "end": 809,
                    "text": "[34,",
                    "ref_id": "BIBREF34"
                },
                {
                    "start": 810,
                    "end": 813,
                    "text": "35]",
                    "ref_id": "BIBREF35"
                }
            ],
            "ref_spans": [],
            "section": "La biodistribution de la chlorpromazine, un avantage dans le traitement du COVID-19"
        },
        {
            "text": "La crise sanitaire actuelle oblige \u00e0 rechercher dans l'urgence des mol\u00e9cules potentiellement utiles pour r\u00e9duire la contagiosit\u00e9, la s\u00e9v\u00e9rit\u00e9 et la l\u00e9talit\u00e9 de cette infection. Le repositionnement de mol\u00e9cules existantes et approuv\u00e9es comme m\u00e9dicaments est une strat\u00e9gie alternative \u00e0 la d\u00e9couverte de nouvelles mol\u00e9cules puisqu'elle permet d'\u00e9liminer de nombreuses \u00e9tapes de d\u00e9veloppement en d\u00e9ployant une th\u00e9rapeutique dont les effets secondaires sont connus et que les m\u00e9decins savent d\u00e9j\u00e0 manier.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "La biodistribution de la chlorpromazine, un avantage dans le traitement du COVID-19"
        },
        {
            "text": "La chlorpromazine, largement utilis\u00e9e en psychiatrie, b\u00e9n\u00e9ficie d'un excellent profil de tol\u00e9rance : ses effets ind\u00e9sirables sont connus -effets anticholinergiques (s\u00e9dation, bouche s\u00e8che, constipation, r\u00e9tention urinaire), allongement du QT et rarement des syndromes malins -et faciles \u00e0 prendre en charge. Les indications psychiatriques qui poss\u00e8dent l'AMM sont les \u00ab \u00e9tats psychotiques aigus \u00bb et \u00ab chroniques \u00bb ainsi que les \u00ab \u00e9tats d'agitation et d'agressivit\u00e9 au cours des \u00e9tats psychotiques aigus et chroniques \u00bb. La seule indication non psychiatrique qui poss\u00e8de l'AMM est la \u00ab pr\u00e9paration \u00e0 l'anesth\u00e9sie \u00bb et \u00ab l'anesth\u00e9sie potentialis\u00e9e \u00bb, mais la chlorpromazine est \u00e9galement utilis\u00e9e en routine clinique sur des populations de patients fragiles : les naus\u00e9es et vomissements pharmacor\u00e9sistants chez la femme enceinte [36] et en oncologie pour les patients souffrant de cancers \u00e0 un stade avanc\u00e9 [37] ; ainsi que pour diverses indications neurologiques, dans le traitement des c\u00e9phal\u00e9es [38, 39] .",
            "cite_spans": [
                {
                    "start": 829,
                    "end": 833,
                    "text": "[36]",
                    "ref_id": "BIBREF36"
                },
                {
                    "start": 907,
                    "end": 911,
                    "text": "[37]",
                    "ref_id": "BIBREF37"
                },
                {
                    "start": 998,
                    "end": 1002,
                    "text": "[38,",
                    "ref_id": "BIBREF38"
                },
                {
                    "start": 1003,
                    "end": 1006,
                    "text": "39]",
                    "ref_id": "BIBREF39"
                }
            ],
            "ref_spans": [],
            "section": "La biodistribution de la chlorpromazine, un avantage dans le traitement du COVID-19"
        },
        {
            "text": "La question de la posologie de chlorpromazine qui serait requise pour obtenir un effet anti-SARS-CoV-2 chez l'homme n'est pas connue, premi\u00e8rement parce qu'il est difficile d'estimer les posologies efficaces in vivo \u00e0 partir de doses efficaces in vitro, et deuxi\u00e8mement parce qu'il n'existe pas de donn\u00e9es chez l'animal sur l'effet anti-coronavirus de la chlorpromazine. Cependant, il est important de noter que les doses efficaces pour inhiber in vitro la r\u00e9plication virale des coronavirus MERS-CoV et SARS-CoV-1 \u00e9taient des doses non toxiques pour les cellules [9] [10] [11] . De plus, une \u00e9tude r\u00e9alis\u00e9e in vivo chez l'animal a pu montrer une efficacit\u00e9 antivirale (contre les ad\u00e9novirus) de la chlorpromazine \u00e0 des doses utilis\u00e9es chez l'humain [40] . Enfin, l'observation de la faible pr\u00e9valence de SARS-CoV-2 chez nos patients souffrant de troubles psychiatriques sugg\u00e8re une dose efficace chez l'homme de l'ordre de celle utilis\u00e9e \u00e0 vis\u00e9e antipsychotique.",
            "cite_spans": [
                {
                    "start": 564,
                    "end": 567,
                    "text": "[9]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 568,
                    "end": 572,
                    "text": "[10]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 573,
                    "end": 577,
                    "text": "[11]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 750,
                    "end": 754,
                    "text": "[40]",
                    "ref_id": "BIBREF40"
                }
            ],
            "ref_spans": [],
            "section": "La biodistribution de la chlorpromazine, un avantage dans le traitement du COVID-19"
        },
        {
            "text": "\u00c9tude pilote sur l'efficacit\u00e9 de la chlorpromazine dans le COVID-19",
            "cite_spans": [],
            "ref_spans": [],
            "section": "La biodistribution de la chlorpromazine, un avantage dans le traitement du COVID-19"
        },
        {
            "text": "Objectifs de l'\u00e9tude reCoVery En int\u00e9grant tous ces \u00e9l\u00e9ments, notre hypoth\u00e8se est que la chlorpromazine pourrait diminuer l'\u00e9volution d\u00e9favorable de l'infection COVID-19 lorsqu'elle est administr\u00e9e d\u00e8s l'apparition de signes respiratoires et r\u00e9duire la contagiosit\u00e9 du SARS-CoV-2. Pour tester cette hypoth\u00e8se, nous avons mis en place le projet de recherche reCoVery (repurposing of chlorpromazine in CoVid-19 treatment), un essai th\u00e9rapeutique pilote de phase III multicentrique, randomis\u00e9, contr\u00f4l\u00e9 et en simple insu.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "La biodistribution de la chlorpromazine, un avantage dans le traitement du COVID-19"
        },
        {
            "text": "La population \u00e9tudi\u00e9e concerne les patients souffrant de COVID-19 chez qui une hospitalisation est requise pour prendre en charge des sympt\u00f4mes respiratoires. Les patients n\u00e9cessitant ou ayant n\u00e9cessit\u00e9 des soins r\u00e9animatoires avec ventilation m\u00e9canique ne seront pas inclus dans cette \u00e9tude. En effet, les m\u00e9canismes d'action de la chlorpromazine ciblent l'entr\u00e9e du virus dans la cellule, bloquant la r\u00e9plication virale au stade pr\u00e9coce de l'infection, ce qui laisse pr\u00e9sager une plus grande efficacit\u00e9 de cette mol\u00e9cule en d\u00e9but de maladie. De plus, la r\u00e9duction de la pr\u00e9valence des formes symptomatiques et virulentes de cette infection chez nos patients, en comparaison aux soignants, renforce l'hypoth\u00e8se d'une efficacit\u00e9 de la chlorpromazine plus probable aux stades pr\u00e9coces de la maladie.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "La biodistribution de la chlorpromazine, un avantage dans le traitement du COVID-19"
        },
        {
            "text": "Les patients seront randomis\u00e9s \u00e0 l'inclusion entre le groupe traitement standard (standard-of-care, SOC) seul et le groupe chlorpromazine en association avec le traitement standard (CPZ + SOC). Les patients du groupe CPZ + SOC recevront jusqu'\u00e0 300 mg par jour de CPZ jusqu'\u00e0 ce que les crit\u00e8res de gu\u00e9rison soient remplis (d\u00e9finis par l'avis du 16 mars 2020 du Haut Conseil de la Sant\u00e9 Publique, [41] ), dans une limite de 21 jours maximum.",
            "cite_spans": [
                {
                    "start": 397,
                    "end": 401,
                    "text": "[41]",
                    "ref_id": "BIBREF41"
                }
            ],
            "ref_spans": [],
            "section": "La biodistribution de la chlorpromazine, un avantage dans le traitement du COVID-19"
        },
        {
            "text": "L'objectif principal de l'\u00e9tude reCoVery est de d\u00e9montrer un d\u00e9lai de r\u00e9ponse au traitement (\u00ab Time To Response \u00bb, TTR) plus court dans le groupe CPZ + SOC par rapport au groupe SOC. La r\u00e9ponse au traitement est d\u00e9finie par la r\u00e9duction d'au moins un niveau de s\u00e9v\u00e9rit\u00e9 \u00e0 la World Health Organization Ordinal Scale for Clinical Improvement (WHO-OSCI, [42] ).",
            "cite_spans": [
                {
                    "start": 351,
                    "end": 355,
                    "text": "[42]",
                    "ref_id": "BIBREF42"
                }
            ],
            "ref_spans": [],
            "section": "La biodistribution de la chlorpromazine, un avantage dans le traitement du COVID-19"
        },
        {
            "text": "Les objectifs secondaires sont de d\u00e9montrer dans le groupe CPZ + SOC, par rapport au groupe SOC :",
            "cite_spans": [],
            "ref_spans": [],
            "section": "La biodistribution de la chlorpromazine, un avantage dans le traitement du COVID-19"
        },
        {
            "text": "-A. une am\u00e9lioration clinique sup\u00e9rieure, -B. une diminution sup\u00e9rieure des marqueurs biologiques de l'atteinte virale par le SARS-CoV-2 (PCR, charge virale), -C. une diminution sup\u00e9rieure des marqueurs inflammatoires (tels que la CRP et la lymphop\u00e9nie), -D. une diminution sup\u00e9rieure de l'atteinte parenchymateuse (TDM thoracique) au septi\u00e8me jour post-randomisation ; -E. de d\u00e9finir la posologie optimale de CPZ et sa tol\u00e9rance, -F. d'\u00e9valuer les param\u00e8tres biologiques de r\u00e9ponse au traitement, notamment l'implication des cytokines inflammatoires.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "La biodistribution de la chlorpromazine, un avantage dans le traitement du COVID-19"
        },
        {
            "text": "L'\u00e9tude reCoVery et ses objectifs sont conformes aux recommandations de l'OMS pour mener des \u00e9tudes pilotes dans la prise en charge th\u00e9rapeutique du COVID-19 (42) .",
            "cite_spans": [
                {
                    "start": 158,
                    "end": 162,
                    "text": "(42)",
                    "ref_id": "BIBREF42"
                }
            ],
            "ref_spans": [],
            "section": "La biodistribution de la chlorpromazine, un avantage dans le traitement du COVID-19"
        },
        {
            "text": "Le b\u00e9n\u00e9fice attendu pour les personnes se pr\u00eatant \u00e0 la recherche est une diminution de l'\u00e9volution d\u00e9favorable de l'infection COVID-19, c'est-\u00e0-dire une diminution de la dur\u00e9e de la maladie, de la dur\u00e9e des soins hospitaliers, de la dur\u00e9e de l'oxyg\u00e9noth\u00e9rapie, du recours \u00e0 la ventilation m\u00e9canique ou \u00e0 la ventilation non invasive, et de la mortalit\u00e9. Un autre b\u00e9n\u00e9fice possible est la diminution de l'anxi\u00e9t\u00e9 fr\u00e9quemment associ\u00e9e \u00e0 la dyspn\u00e9e du COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "La biodistribution de la chlorpromazine, un avantage dans le traitement du COVID-19"
        },
        {
            "text": "Les risques pr\u00e9visibles pour les personnes se pr\u00eatant \u00e0 la recherche sont les effets ind\u00e9sirables bien connus de la chlorpromazine. Ces risques seront limit\u00e9s par une surveillance hospitali\u00e8re durant toute la dur\u00e9e de d\u00e9livrance du traitement par chlorpromazine ainsi qu'une surveillance sp\u00e9cifique de ses effets ind\u00e9sirables potentiellement graves : dosages r\u00e9guliers des CPK pour d\u00e9pister un syndrome malin des neuroleptiques, examens cliniques quotidiens, ECG r\u00e9guliers. Aussi, comme mentionn\u00e9 plus haut, la chlorpromazine est d\u00e9j\u00e0 utilis\u00e9e \u00e0 des posologies \u00e9lev\u00e9es dans des indications nonpsychiatriques et parfois chez des populations fragiles, notamment dans le traitement des vomissements pharmacor\u00e9sistants en canc\u00e9rologie ou h\u00e9matologie et chez des patients avec sepsis et parfois d\u00e9faillance d'organes [37] . Les posologies utilis\u00e9es peuvent alors \u00eatre de 12,5 mg \u00e0 100 mg IVSE toutes les quatre heures [37] . Enfin, il est important de noter que la chlorpromazine n'\u00e9tant pas un d\u00e9presseur respiratoire, ce m\u00e9dicament n'est pas contre-indiqu\u00e9 chez les patients souffrant d'une insuffisance respiratoire s\u00e9v\u00e8re, contrairement \u00e0 d'autres anxiolytiques comme les benzodiaz\u00e9pines.",
            "cite_spans": [
                {
                    "start": 812,
                    "end": 816,
                    "text": "[37]",
                    "ref_id": "BIBREF37"
                },
                {
                    "start": 913,
                    "end": 917,
                    "text": "[37]",
                    "ref_id": "BIBREF37"
                }
            ],
            "ref_spans": [],
            "section": "S\u00e9curit\u00e9 des patients inclus"
        },
        {
            "text": "L'originalit\u00e9 de l'\u00e9tude reCoVery repose sur le repositionnement de la chlorpromazine -mol\u00e9cule d\u00e9couverte il y a 68 ans, largement utilis\u00e9e en psychiatrie et avec un excellent profil de tol\u00e9rance -dans le traitement de la pand\u00e9mie actuelle de COVID-19 pour laquelle il n'existe \u00e0 ce jour aucun traitement de r\u00e9f\u00e9rence. Le b\u00e9n\u00e9fice th\u00e9rapeutique potentiel de la chlorpromazine contre le COVID-19 repose \u00e0 la fois sur l'observation dans plusieurs unit\u00e9s psychiatriques d'une faible propagation des formes symptomatiques de COVID-19 parmi les patients et sur des arguments virologiques.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusion"
        },
        {
            "text": "La chlorpromazine, dont le nom commercial, Largactil, lui a \u00e9t\u00e9 donn\u00e9 en r\u00e9f\u00e9rence \u00e0 sa 'large action', pr\u00e9sente en effet de nombreuses propri\u00e9t\u00e9s : antipsychotique, anxiolytique, anti\u00e9m\u00e9tique, antiviral, inhibition de l'endocytose d\u00e9pendante des clathrines, modulateur du fonctionnement de la barri\u00e8re h\u00e9mato-enc\u00e9phalique, effets immunomodulateurs\u2026 La chlorpromazine a d\u00e9j\u00e0 d\u00e9montr\u00e9 son effet antiviral in vitro contre le SARS-CoV-1 et le MERS-CoV, deux coronavirus proches du SARS-CoV-2. Les effets immunomodulateurs de la chlorpromazine pourraient aussi ouvrir des perspectives quant \u00e0 son \u00e9ventuel int\u00e9r\u00eat dans les formes s\u00e9v\u00e8res de COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusion"
        },
        {
            "text": "La d\u00e9couverte des propri\u00e9t\u00e9s de la chlorpromazine, comme pour bien d'autres mol\u00e9cules en psychiatrie, est \u00e0 la fois le fruit de la s\u00e9rendipit\u00e9 et d'observations cliniques attentives. C'est ainsi que le domaine de la maladie mentale pourrait apporter des pistes th\u00e9rapeutiques innovantes dans la lutte contre le SARS-CoV-2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusion"
        },
        {
            "text": "Les auteurs d\u00e9clarent ne pas avoir de liens d'int\u00e9r\u00eats.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Liens d'int\u00e9r\u00eats"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "European Centre for Disease Prevention and Control",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Influence of chlorpromazine on the replication of influenza virus in chick embryo cells",
            "authors": [
                {
                    "first": "O",
                    "middle": [],
                    "last": "Krizanov\u00e1",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Ciampor",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Veber",
                    "suffix": ""
                }
            ],
            "year": 1982,
            "venue": "Acta Virol",
            "volume": "26",
            "issn": "",
            "pages": "209--225",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Inhibition of HIV infection of H9 cells by chlorpromazine derivatives",
            "authors": [
                {
                    "first": "I",
                    "middle": [],
                    "last": "Hewlett",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Molnar",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Foldeak",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "S"
                    ],
                    "last": "Pine",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Weaver",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "J Acquir Immune Defic Syndr Hum Retrovirol",
            "volume": "15",
            "issn": "",
            "pages": "16--20",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "JC virus enters human glial cells by clathrin-dependent receptormediated endocytosis",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "T"
                    ],
                    "last": "Pho",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Ashok",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "J"
                    ],
                    "last": "Atwood",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Journal of Virology",
            "volume": "74",
            "issn": "",
            "pages": "2288--92",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Interference in Japanese encephalitis virus infection of Vero cells by a cationic amphiphilic drug, chlorpromazine",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Nawa",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Takasaki",
                    "suffix": ""
                },
                {
                    "first": "K-I",
                    "middle": [],
                    "last": "Yamada",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Kurane",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Akatsuka",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "J Gen Virol",
            "volume": "84",
            "issn": "",
            "pages": "1737--1778",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Hepatitis C virus entry depends on clathrin-mediated endocytosis",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Blanchard",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Belouzard",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Goueslain",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Wakita",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Dubuisson",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wychowski",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Journal of Virology",
            "volume": "80",
            "issn": "",
            "pages": "6964--72",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Pohjala",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Utt",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Varjak",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Lulla",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Merits",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Ahola",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "PLOS ONE",
            "volume": "6",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "H"
                    ],
                    "last": "De Wilde",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Jochmans",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "C"
                    ],
                    "last": "Posthuma",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Zevenhoven-Dobbe",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Van Nieuwkoop",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "M"
                    ],
                    "last": "Bestebroer",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Antimicrob Agents Chemother",
            "volume": "58",
            "issn": "",
            "pages": "4875--84",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Dyall",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Coleman",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Hart",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Venkataraman",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "R"
                    ],
                    "last": "Holbrook",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Kindrachuk",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Antimicrob Agents Chemother",
            "volume": "58",
            "issn": "",
            "pages": "4885--93",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Cong",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Hart",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Gross",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Frieman",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Bollinger",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "PLOS ONE",
            "volume": "13",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Phenothiazine-derived antipsychotic drugs inhibit dynamin and clathrin-mediated endocytosis",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Daniel",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Chau",
                    "suffix": ""
                },
                {
                    "first": "Abdel-Hamid",
                    "middle": [],
                    "last": "Mk",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Von Kleist",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Whiting",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Traffic",
            "volume": "16",
            "issn": "",
            "pages": "635--54",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "H"
                    ],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "G"
                    ],
                    "last": "Rothberg",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "G"
                    ],
                    "last": "Anderson",
                    "suffix": ""
                }
            ],
            "year": 1993,
            "venue": "J Cell Biol",
            "volume": "123",
            "issn": "",
            "pages": "1107--1124",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Burkard",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "H"
                    ],
                    "last": "Verheije",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Wicht",
                    "suffix": ""
                },
                {
                    "first": "Kasteren",
                    "middle": [],
                    "last": "Siv",
                    "suffix": ""
                },
                {
                    "first": "Kuppeveld",
                    "middle": [],
                    "last": "Fjv",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "L"
                    ],
                    "last": "Haagmans",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "PLOS Pathogens",
            "volume": "10",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "H-M",
                    "middle": [],
                    "last": "Shen",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Int J Biol Sci",
            "volume": "16",
            "issn": "",
            "pages": "1724--1755",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "China. JAMA",
            "volume": "323",
            "issn": "",
            "pages": "1061--1070",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "A Novel Coronavirus from Patients with Pneumonia in China",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "N Engl J Med",
            "volume": "382",
            "issn": "",
            "pages": "727--760",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "J"
                    ],
                    "last": "Giamarellos-Bourboulis",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "Netea",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Rovina",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Akinosoglou",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Antoniadou",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Antonakos",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Host Microbe",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Effects of antipsychotic drugs on cytokine networks",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Pollm\u00e4cher",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Haack",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Schuld",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Kraus",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Hinze-Selch",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Journal of Psychiatric Research",
            "volume": "34",
            "issn": "",
            "pages": "369--82",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Chlorpromazine-induced immunopathy: progressive increase in serum IgM",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zucker",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "M"
                    ],
                    "last": "Zarrabi",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "H"
                    ],
                    "last": "Schubach",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Varma",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Derman",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "M"
                    ],
                    "last": "Lysik",
                    "suffix": ""
                }
            ],
            "year": 1990,
            "venue": "Medicine (Baltimore)",
            "volume": "69",
            "issn": "",
            "pages": "92--100",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Pharmacological activities of chlorpromazine involved in the inhibition of tumour necrosis factor production in vivo in mice",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Bertini",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Garattini",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Delgado",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Ghezzi",
                    "suffix": ""
                }
            ],
            "year": 1993,
            "venue": "Immunology",
            "volume": "79",
            "issn": "",
            "pages": "217--226",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Gadina",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Bertini",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Mengozzi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Zandalasini",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mantovani",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Ghezzi",
                    "suffix": ""
                }
            ],
            "year": 1991,
            "venue": "J Exp Med",
            "volume": "173",
            "issn": "",
            "pages": "1305--1315",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Chlorpromazine specifically inhibits peripheral and brain TNF production, and up-regulates IL-10 production, in mice",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Mengozzi",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Fantuzzi",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Faggioni",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Marchant",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Goldman",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Orencole",
                    "suffix": ""
                }
            ],
            "year": 1994,
            "venue": "Immunology",
            "volume": "82",
            "issn": "",
            "pages": "207--217",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Tarazona",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Gonz\u00e1lez-Garc\u00eda",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Zamzami",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Marchetti",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Frechin",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Gonzalo",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "J Immunol",
            "volume": "154",
            "issn": "",
            "pages": "861--70",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Distribution of chlorpromazine and imipramine in adipose and other tissues of rats",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "H"
                    ],
                    "last": "Bickel",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "E"
                    ],
                    "last": "Graber",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Moor",
                    "suffix": ""
                }
            ],
            "year": 1983,
            "venue": "Life Sci",
            "volume": "33",
            "issn": "",
            "pages": "2025--2056",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Rat tissue concentrations of chlorimipramine, chlorpromazine and their N-demethylated metabolites after a single oral dose of the parent compounds",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "P"
                    ],
                    "last": "Sgaragli",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Valoti",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Palmi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Frosini",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "Giovannini",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Bianchi",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "J Pharm Pharmacol",
            "volume": "47",
            "issn": "",
            "pages": "782--90",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Distribution of chlorpromazine metabolites in selected organs of psychiatric patients chronically dosed up to the time of death",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "S"
                    ],
                    "last": "Forrest",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "G"
                    ],
                    "last": "Bolt",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "T"
                    ],
                    "last": "Serra",
                    "suffix": ""
                }
            ],
            "year": 1968,
            "venue": "Biochem Pharmacol",
            "volume": "17",
            "issn": "",
            "pages": "2061--70",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. The Lancet Microbe",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Chu",
                    "suffix": ""
                },
                {
                    "first": "Jf-W",
                    "middle": [],
                    "last": "Chan",
                    "suffix": ""
                },
                {
                    "first": "Tt-T",
                    "middle": [],
                    "last": "Yuen",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Shuai",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Yuan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "doi.org/10.1016/S2666-5247(20)30004-5"
                ]
            }
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Test dose response in schizophrenia: chlorpromazine blood and saliva levels",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "R"
                    ],
                    "last": "May",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Van Putten",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Jenden",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "K"
                    ],
                    "last": "Cho",
                    "suffix": ""
                }
            ],
            "year": 1978,
            "venue": "Arch Gen Psychiatry",
            "volume": "35",
            "issn": "",
            "pages": "1091--1098",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Rundle-Thiele",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Head",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Cosgrove",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "H"
                    ],
                    "last": "Martin",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Br J Clin Pharmacol",
            "volume": "81",
            "issn": "",
            "pages": "199--209",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Nervous system involvement after infection with COVID-19 and other coronaviruses",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Duan",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Hashimoto",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Brain Behav Immun",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.bbi.2020.03.031"
                ]
            }
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Brain distribution and kinetics of 11C-chlorpromazine in schizophrenics: positron emission tomography studies",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Comar",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Zarifian",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Verhas",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Soussaline",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Maziere",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Berger",
                    "suffix": ""
                }
            ],
            "year": 1979,
            "venue": "Psychiatry Res",
            "volume": "1",
            "issn": "",
            "pages": "23--32",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "The distribution of 35S-chlorpromazine in mice studied by whole body autoradiography",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "E"
                    ],
                    "last": "Sj\u00f6strand",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "B"
                    ],
                    "last": "Cassano",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Hansson",
                    "suffix": ""
                }
            ],
            "year": 1965,
            "venue": "Arch Int Pharmacodyn Ther",
            "volume": "156",
            "issn": "",
            "pages": "34--47",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Drug distribution between blood and brain as a determinant of antipsychotic drug effects",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tsuneizumi",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Babb",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "M"
                    ],
                    "last": "Cohen",
                    "suffix": ""
                }
            ],
            "year": 1992,
            "venue": "Biol Psychiatry",
            "volume": "32",
            "issn": "",
            "pages": "817--841",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "The distribution and metabolism of chlorpromazine in rats and the relationship to effects on cerebral monoamine metabolism",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "A"
                    ],
                    "last": "Wiesel",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Alfredsson",
                    "suffix": ""
                }
            ],
            "year": 1976,
            "venue": "Eur J Pharmacol",
            "volume": "40",
            "issn": "",
            "pages": "263--72",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "Committee on Practice B-O. ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy",
            "authors": [],
            "year": 2018,
            "venue": "Obstet Gynecol",
            "volume": "131",
            "issn": "",
            "pages": "15--30",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "Nausea and Vomiting in Advanced Cancer-The Cleveland Clinic Protocol (TH310)",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Gupta",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Davis",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Walsh",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Legrand",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Lagman",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Parala-Metz",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "J Pain Symptom Manage",
            "volume": "45",
            "issn": "",
            "pages": "338--347",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Marmura",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "D"
                    ],
                    "last": "Silberstein",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "J"
                    ],
                    "last": "Schwedt",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Headache: The Journal of Head and Face Pain",
            "volume": "55",
            "issn": "",
            "pages": "3--20",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Parenteral Treatment of Episodic Tension-Type Headache: A Systematic Review",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Weinman",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Nicastro",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Akala",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "W"
                    ],
                    "last": "Friedman",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Headache: The Journal of Head and Face Pain",
            "volume": "54",
            "issn": "",
            "pages": "260--268",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Kanerva",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Raki",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Ranki",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "S\u00e4rkioja",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Koponen",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Desmond",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "J Gene Med",
            "volume": "9",
            "issn": "",
            "pages": "3--9",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "Coronavirus SARS-CoV-2 : crit\u00e8res cliniques de sortie d'isolement des patients infect\u00e9s. Paris: Haut Conseil de la Sant\u00e9 Publique",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Hcsp",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "WHO | Coronavirus disease (COVID-2019) R&D. WHO",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "\u00e9pid\u00e9mie de coronavirus apr\u00e8s le SARS-CoV-1 en 2003 et le MERS-CoV en 2012. Nous avons observ\u00e9 dans le GHU PARIS Psychiatrie & Neurosciences (site Sainte-Anne, Paris, France) une incidence moins importante de formes symptomatiques de COVID-19 chez les patients (environ 4 % dans le P\u00f4le Hospitalo-Universitaire de psychiatrie Paris 15) que dans notre personnel soignant (environ 14 % des infirmiers et des m\u00e9decins de ce m\u00eame p\u00f4le). Des retours similaires nous sont donn\u00e9s par les unit\u00e9s psyCOVID en France, en Espagne et en Italie. Ces observations nous ont amen\u00e9s \u00e0 formuler l'hypoth\u00e8se que les traitements psychotropes pourraient avoir une action prophylactique sur le SARS-CoV-2 et prot\u00e9geraient les patients des formes symptomatiques et virulentes de cette infection.",
            "latex": null,
            "type": "figure"
        }
    },
    "back_matter": []
}